{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:56:39Z","timestamp":1782975399956,"version":"3.54.5"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T00:00:00Z","timestamp":1424908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0003501","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T18:52:30Z","timestamp":1424976750000},"page":"e0003501","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":41,"title":["Minipool Caprylic Acid Fractionation of Plasma Using Disposable Equipment: A Practical Method to Enhance Immunoglobulin Supply in Developing Countries"],"prefix":"10.1371","volume":"9","author":[{"given":"Magdy","family":"El-Ekiaby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e1ngela","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makram","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Gorgy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Goubran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Radosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Burnouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,2,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tmrv.2006.11.001","article-title":"Modern plasma fractionation","volume":"21","author":"T Burnouf","year":"2007","journal-title":"Transfus Med Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-3148.2009.00963.x","article-title":"Solvent-detergent filtered (S\/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system","volume":"20","author":"M El-Ekiaby","year":"2010","journal-title":"Transfus Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1423-0410.2006.00772.x","article-title":"A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system","volume":"91","author":"T Burnouf","year":"2006","journal-title":"Vox Sang"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1111\/j.1537-2995.2006.01035.x","article-title":"A process for solvent\/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system","volume":"46","author":"T Burnouf","year":"2006","journal-title":"Transfusion"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"g5539","DOI":"10.1136\/bmj.g5539","article-title":"First Ebola treatment is approved by WHO","volume":"349","author":"A Gulland","year":"2014","journal-title":"British Medical Journal"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(14)61693-7","article-title":"Ebola: a call for blood transfusion strategy in sub-Saharan Africa","volume":"384","author":"T Burnouf","year":"2014","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1365-2516.2008.01797.x","article-title":"Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems","volume":"14","author":"T Burnouf","year":"2008","journal-title":"Haemophilia"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"UK Laemmli","year":"1970","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/trf.12243","article-title":"Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI\/activated FXI from human plasma IgG","volume":"54","author":"YW Wu","year":"2014","journal-title":"Transfusion"},{"key":"ref10","article-title":"Human plasma-derived immunoglobulin G fractionated by an aqueous two-phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in vitro thrombogenic activity","author":"M Vargas","year":"2015","journal-title":"Vox Sang"},{"key":"ref11","unstructured":"CPMP (1996) Note for Guidance on Virus Validation Studies: the Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses (revised). CPMP\/BWP\/CPMP\/5136\/03. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.emea.eu.int\" xlink:type=\"simple\">http:\/\/www.emea.eu.int<\/ext-link>. London: European Agency for the Evaluation of Medicinal Products (EMEA)."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1423-0410.2009.01226.x","article-title":"Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance","volume":"98","author":"M Radosevich","year":"2010","journal-title":"Vox Sanguinis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.biologicals.2009.01.005","article-title":"Plasma fractionation issues","volume":"37","author":"A Farrugia","year":"2009","journal-title":"Biologicals"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10826068408070610","article-title":"Preparation of human immunoglobulin by caprylic acid precipitation","volume":"14","author":"AF Habeeb","year":"1984","journal-title":"Prep Biochem"},{"key":"ref15","first-page":"1054","article-title":"Isolation of IgG immunoglobulin from human plasma using caprylic acid","volume":"14","author":"M Steinbuch","year":"1969","journal-title":"Rev Fr Etud Clin Biol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1423-0410.2005.00731.x","article-title":"A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance","volume":"90","author":"J Parkkinen","year":"2006","journal-title":"Vox Sang"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1423-0410.2003.00285.x","article-title":"Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography","volume":"84","author":"W Lebing","year":"2003","journal-title":"Vox Sang"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/biol.2002.0332","article-title":"Inactivation of Lipid Enveloped Viruses by Octanoic Acid Treatment of Immunoglobulin Solution","volume":"30","author":"H Dichtelm\u00fcller","year":"2002","journal-title":"Biologicals"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0041-0101(94)90087-6","article-title":"Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production","volume":"32","author":"G Rojas","year":"1994","journal-title":"Toxicon"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0041-0101(98)00220-7","article-title":"A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms","volume":"37","author":"R Otero","year":"1999","journal-title":"Toxicon"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1002\/bit.24539","article-title":"Caprylic acid precipitation method for impurity reduction: an alternative to conventional chromatography for monoclonal antibody purification","volume":"109","author":"Y Brodsky","year":"2012","journal-title":"Biotechnol Bioeng"},{"key":"ref22","article-title":"The entity of immunoglobulin A-related anaphylactic transfusion reactions is not evidence based","author":"SG Sandler","year":"2014","journal-title":"Transfusion"},{"key":"ref23","article-title":"Universal pooled plasma (Uniplas) does not induce complement-mediated hemolysis of human red blood cells in vitro","author":"A Heger","year":"2014","journal-title":"Transfus Apher Sci"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1537-2995.2012.03589.x","article-title":"Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010","volume":"52","author":"GW Daniel","year":"2012","journal-title":"Transfusion"},{"key":"ref25","first-page":"WMC002002","article-title":"Identification of activated FXI as the major biochemical root cause in IVIG batches associated with thromboembolic events. Analytical and experimental approaches resulting in corrective and preventive measures implemented into the Octagam\u00ae manufacturing process","volume":"2","author":"JR Roemisch","year":"2011","journal-title":"Immunotherapy 2011"},{"key":"ref26","article-title":"Monograph on human normal immunoglobulin for intravenous administration (0918): 01\/2012, European Pharmacopoeia, Strasbourg (France), Council of Europe, 2012","year":"2012"},{"key":"ref27","unstructured":"FDA-Workshop (2011) Risk mitigation strategies to address potential procoagulant activity in immune globulin products. In: Administration FD, editor. http:\/\/wwwfdagov\/downloads\/BiologicsBloodVaccines\/NewsEvents\/WorkshopsMeetingsConferences\/UCM258022pdf."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.biologicals.2014.04.002","article-title":"Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products","volume":"42","author":"WA Germishuizen","year":"2014","journal-title":"Biologicals"},{"key":"ref29","unstructured":"WHO (2005) Recommendations for the production, quality control and regulation of plasma for fractionation. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/bloodproducts\" xlink:type=\"simple\">http:\/\/www.who.int\/bloodproducts<\/ext-link>."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1054\/blre.2000.0129","article-title":"Reducing the risk of infection from plasma products: specific preventative strategies","volume":"14","author":"T Burnouf","year":"2000","journal-title":"Blood Rev"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biologicals.2009.10.015","article-title":"Nucleic acid testing (NAT) in high prevalence-low resource settings","volume":"38","author":"M El Ekiaby","year":"2010","journal-title":"Biologicals"},{"key":"ref32","first-page":"1","year":"2003"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/biol.2002.0334","article-title":"Enveloped virus inactivation by caprylate: A robust alternative to solvent-detergent treatment in plasma derived intermediates","volume":"30","author":"M Korneyeva","year":"2002","journal-title":"Biologicals"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.biologicals.2007.02.004","article-title":"Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins","volume":"35","author":"M Mpandi","year":"2007","journal-title":"Biologicals"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.biologicals.2006.11.003","article-title":"Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms","volume":"35","author":"T Burnouf","year":"2007","journal-title":"Biologicals"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/btpr.1758","article-title":"Safety of snake antivenom immunoglobulins: efficacy of viral inactivation in a complete downstream process","volume":"29","author":"CP Caricati","year":"2013","journal-title":"Biotechnol Prog"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2516.2003.00701.x","article-title":"Nanofiltration of plasma-derived biopharmaceutical products","volume":"9","author":"T Burnouf","year":"2003","journal-title":"Haemophilia"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.biologicals.2009.05.003","article-title":"Assessment of the impact of solvent\/detergent treatment on the quality and potency of a whole IgG equine antivenom","volume":"37","author":"A Segura","year":"2009","journal-title":"Biologicals"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/voxs.12099","article-title":"New approaches for manufacturing plasma derivatives","volume":"9","author":"T Burnouf","year":"2014","journal-title":"ISBT Science Series"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.transci.2014.10.003","article-title":"Ebola virus convalescent blood products: Where we are now and where we may need to go","volume":"51","author":"T Burnouf","year":"2014","journal-title":"Transfus Apher Sci"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0003501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T07:26:04Z","timestamp":1589009164000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0003501"}},"subtitle":[],"editor":[{"given":"Joseph M.","family":"Vinetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,2,26]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0003501","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,26]]}}}